Why is TG Therapeutics (TGTX) stock down today?

TG Therapeutics fell 11.26% to $46.17 — from a previous close of $52.03 — after reporting Q2 2026 results that badly missed the earnings-per-share estimate. The company posted EPS of $0.05 against a Wall Street consensus estimate of roughly $0.44, a gap large enough to trigger heavy selling even though revenue came in above expectations and the company raised its 2026 revenue outlook.

The raised guidance added another layer of investor frustration: while TG Therapeutics lifted its full-year revenue view citing strong sales growth of its multiple-sclerosis drug Briumvi, the updated outlook still came in below analyst forecasts. The CEO stated on the Q2 earnings call that Briumvi is on track to become a $1 billion drug in the U.S., but that forward-looking confidence was not enough to offset the immediate EPS disappointment.

The move stands out against a strongly positive market backdrop. The S&P 500 rose 1.48% and the Nasdaq-100 (tracked by QQQ) gained 1.76% on the same day — meaning TG Therapeutics dropped roughly 13 percentage points more than the broader market, underscoring that the selling was driven by company-specific news rather than any macro selloff.

As of the close, TG Therapeutics carries a market capitalization of approximately $7.07 billion. The stock traded in a wide intraday range of $45.84 to $52.36, reflecting the volatility that accompanied the earnings release and subsequent call. The company's next major market-moving event on the calendar is the August 7 jobs report, which could influence the broader biotech tape but is not directly tied to TGTX's business.